atai Impact at PS2023

Psychedelic Science 2023 Announces Track Sponsor atai Impact

February 8th, 2023

Today, Psychedelic Science 2023, hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced atai Impact has joined the event as a Scientific Research Track Sponsor.

With an estimated 10,000 attendees, Psychedelic Science 2023 will be the world’s largest gathering of the psychedelic ecosystem, taking place June 19-23, 2023, in Denver, Colorado. The world leading event will feature five days of panels, workshops, and lectures from leaders and visionaries in psychedelic research, education, policy, business, culture, and communities. Conference tracks will be complemented by pre- and post-conference workshops; an exhibit hall; and a marketplace featuring artists, musicians, and other vendors from around the world.

“We’re pleased to be a sponsor of the Scientific Research Track of Psychedelic Science to illuminate the cutting-edge work happening in a year that is expected to be pivotal for our field.  We look forward to gathering with others passionate about and dedicated to bringing innovation to the mental health field,” said Rae Richman, Vice President, atai Impact.

Attendees will include MAPS members, donors, researchers, students, clinicians, advocates, therapists, political leaders, entrepreneurs, executives, investors, psychedelic enthusiasts, and those who may benefit from MAPS’ decades of research and advocacy.

About atai Impact

atai Impact is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

About Momentum Events

Founded in 2012, Momentum Events proudly serves our clients and produces events that attract the best and brightest minds who come together to share their knowledge, connect with the individuals that matter most and enjoy valuable experiences online or in real life. Whether we’re developing cutting edge conferences for the markets we serve, or producing a partner’s next event, Momentum leverages our best in class technology platforms, an assortment of virtual and live event third-party provider relationships, and the meticulous nature of our event planning mindset to deliver true, sustainable value for all stakeholders.

About MAPS

Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $130 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.

atai Impact Media Contact:

Allan Malievsky

Senior Director, External Affairs

Subscribe to the PS2023 newsletter to receive updates on our conference, speakers, events, and other important announcements.